Which has the lower trailing P/E, BMRN or DVA?

DVA has the lower trailing P/E: BMRN trades at 143.92 and DVA at 15.96. P/E is one valuation measure and does not by itself establish which business is cheaper.

Which has grown faster, BMRN or DVA?

Over the past five years, BMRN grew revenue faster — BMRN at a 12.19% CAGR versus DVA at 3.91%.

Is BMRN or DVA more profitable?

DVA runs the higher net margin — BMRN at 2.14% versus DVA at 6.05%.

How have BMRN and DVA total returns compared?

Over the past 10 years, BMRN delivered -4.98% and DVA delivered 10.80% annualized total return. Past performance doesn't predict future results.

BioMarin Pharmaceutical Inc. (BMRN) vs DaVita Inc. (DVA)

A side-by-side comparison of BioMarin Pharmaceutical Inc. and DaVita Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

BMRN

BioMarin Pharmaceutical Inc.

$10.85B

$56.13HealthcareDelayed quote: Oct 6, 2026, 2:50 PM EDT

DVA

DaVita Inc.

$11.66B

$181.62HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT

Total return — BMRN vs DVA

growth of $100 · dividends reinvested · last 10y

BMRN -39.5% (-4.9%/yr)DVA +180.6% (+10.9%/yr)DVA compounded faster over this window

BMRN DVA

BMRN vs DVA: by the numbers

•DVA is the larger company ($11.66B vs $10.85B market cap).
•DVA trades at the lower trailing earnings multiple (15.96 vs 143.92 P/E), one valuation lens rather than an overall verdict.
•DVA converts more revenue to profit (6.05% vs 2.14% net margin).
•BMRN grew revenue faster over the past five years (12.19% vs 3.91% CAGR).

Metrics side by side

Valuation

Metric	BMRN	DVA
P/E ratio	143.92	15.96
Forward P/E	N/A	12.29
PEG ratio	N/A	1.93
P/S ratio	3.18	0.83
P/B ratio	1.72	N/A
EV / EBITDA	33.26	7.72
FCF yield	6.76%	13.80%

Profitability

Metric	BMRN	DVA
Gross margin	75.55%	31.02%
Operating margin	16.56%	15.06%
Net margin	2.14%	6.05%
ROE	1.15%	N/A
ROIC	1.40%	11.18%

Growth (annualized)

Metric	BMRN	DVA
Revenue CAGR (5Y)	12.19%	3.91%
EPS CAGR (5Y)	-17.46%	8.25%
FCF CAGR (5Y)	33.84%	7.44%
Total return CAGR (5Y)	-5.59%	9.22%

Frequently asked

Which has the lower trailing P/E, BMRN or DVA?: DVA has the lower trailing P/E: BMRN trades at 143.92 and DVA at 15.96. P/E is one valuation measure and does not by itself establish which business is cheaper.
Which has grown faster, BMRN or DVA?: Over the past five years, BMRN grew revenue faster — BMRN at a 12.19% CAGR versus DVA at 3.91%.
Is BMRN or DVA more profitable?: DVA runs the higher net margin — BMRN at 2.14% versus DVA at 6.05%.
How have BMRN and DVA total returns compared?: Over the past 10 years, BMRN delivered -4.98% and DVA delivered 10.80% annualized total return. Past performance doesn't predict future results.

Go deeper

Full BMRN analysis Full DVA analysis Interactive comparison tool

Dig into the metrics

BioMarin Pharmaceutical P/E ratio DaVita P/E ratio BioMarin Pharmaceutical ROE DaVita ROE BioMarin Pharmaceutical operating margin DaVita operating margin BioMarin Pharmaceutical revenue growth DaVita revenue growth BioMarin Pharmaceutical free cash flow DaVita free cash flow

BioMarin Pharmaceutical & DaVita appear in these rankings

Highest FCF Yield Stocks

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.